TR201909582T4 - Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi. - Google Patents

Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi. Download PDF

Info

Publication number
TR201909582T4
TR201909582T4 TR2019/09582T TR201909582T TR201909582T4 TR 201909582 T4 TR201909582 T4 TR 201909582T4 TR 2019/09582 T TR2019/09582 T TR 2019/09582T TR 201909582 T TR201909582 T TR 201909582T TR 201909582 T4 TR201909582 T4 TR 201909582T4
Authority
TR
Turkey
Prior art keywords
optionally substituted
compound
substituents
cells
heterocyclyl
Prior art date
Application number
TR2019/09582T
Other languages
English (en)
Turkish (tr)
Inventor
Sauvageau Guy
Gareau Yves
Ruel Réjean
Gingras Stéphane
Fares Iman
Original Assignee
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48872865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201909582(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Montreal filed Critical Univ Montreal
Publication of TR201909582T4 publication Critical patent/TR201909582T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TR2019/09582T 2012-01-27 2013-01-25 Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi. TR201909582T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261591521P 2012-01-27 2012-01-27

Publications (1)

Publication Number Publication Date
TR201909582T4 true TR201909582T4 (tr) 2019-07-22

Family

ID=48872865

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09582T TR201909582T4 (tr) 2012-01-27 2013-01-25 Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi.

Country Status (24)

Country Link
US (3) US9409906B2 (enExample)
EP (1) EP2807165B1 (enExample)
JP (1) JP6250556B2 (enExample)
KR (1) KR102098122B1 (enExample)
CN (1) CN104144931B (enExample)
AU (1) AU2013212457B2 (enExample)
BR (1) BR112014018524B1 (enExample)
CA (1) CA2862140C (enExample)
CY (1) CY1121799T1 (enExample)
DK (1) DK2807165T3 (enExample)
ES (1) ES2733946T3 (enExample)
HR (1) HRP20191189T1 (enExample)
HU (1) HUE044070T4 (enExample)
IL (1) IL233587B (enExample)
LT (1) LT2807165T (enExample)
NZ (1) NZ627188A (enExample)
PL (1) PL2807165T3 (enExample)
PT (1) PT2807165T (enExample)
RS (1) RS59002B1 (enExample)
SG (1) SG11201404241SA (enExample)
SI (1) SI2807165T1 (enExample)
SM (1) SMT201900360T1 (enExample)
TR (1) TR201909582T4 (enExample)
WO (1) WO2013110198A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862140C (en) 2012-01-27 2020-04-21 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
CA2848575C (en) 2013-05-17 2021-01-26 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
EP3110818B1 (en) * 2014-02-28 2019-10-23 The Regents of The University of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
WO2015161373A1 (en) * 2014-04-22 2015-10-29 Université de Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
CN107208111B (zh) * 2014-09-18 2021-07-06 蒙特利尔大学 用于增强病毒基因转移至人造血细胞的化合物和方法
EP3240552A4 (en) * 2014-12-31 2018-06-20 Anthrogenesis Corporation Natural killer cells and uses thereof
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
AU2016273439B2 (en) 2015-06-05 2020-11-05 Héma-Québec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105316293A (zh) * 2015-09-23 2016-02-10 广东颐养抗衰老研究院 一种体外获得造血干/祖细胞的方法
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
MY192848A (en) * 2015-12-28 2022-09-12 Intellia Therapeutics Inc Compositions and methods for the treatment of hemoglobinopathies
JP7080179B2 (ja) 2016-03-15 2022-06-03 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大に関する方法および組成物
CN109843304A (zh) * 2016-05-07 2019-06-04 细胞结构公司 使用自然杀伤细胞治疗急性髓性白血病和多发性骨髓瘤的方法
SG10202101478YA (en) * 2016-08-18 2021-03-30 Nat Univ Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
EP3519577A1 (en) 2016-09-28 2019-08-07 Novartis AG Porous membrane-based macromolecule delivery system
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
AU2018338967B2 (en) 2017-09-29 2025-04-24 Intellia Therapeutics, Inc. In vitro method of mRNA delivery using lipid nanoparticles
SG11202003807RA (en) * 2017-11-03 2020-05-28 Univ Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
US20200338132A1 (en) * 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US12011460B2 (en) 2018-02-20 2024-06-18 Universite De Montreal Expansion of NK and DC cells in vivo mediating immune response
ES2979163T3 (es) * 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
US20230279394A1 (en) 2019-12-18 2023-09-07 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
IL293811A (en) * 2019-12-18 2022-08-01 Univ Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
KR20220122667A (ko) 2019-12-26 2022-09-02 스미토모 파마 가부시키가이샤 조혈 줄기세포의 배양 방법
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2021256977A1 (en) * 2020-06-15 2021-12-23 Subramaniam Agatheeswaran Novel methods and compounds for protein degradation
EP4171593A4 (en) * 2020-06-25 2024-07-03 Angiocrine Bioscience, Inc. Endothelial cells for mitigation of chemotherapy-induced toxicity
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
CA3195653A1 (en) 2020-10-14 2022-04-21 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
WO2022133282A1 (en) 2020-12-18 2022-06-23 Ossium Health, Inc. Methods of cell therapies
TW202309044A (zh) * 2021-04-26 2023-03-01 日商住友製藥股份有限公司 氧呯衍生物
WO2022232839A1 (en) 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
EP4359527A2 (en) 2021-06-23 2024-05-01 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
GB202111169D0 (en) 2021-08-03 2021-09-15 Adaptimmune Ltd Methods of T cell production
CN114736862B (zh) * 2022-05-18 2024-05-28 诺航生物技术研究院徐州有限公司 一种造血干细胞培养基和造血干细胞的体外扩增方法
CN117164593A (zh) * 2023-08-31 2023-12-05 贵州省天然产物研究中心 一种嘧啶并吲哚类化合物及其制备方法和应用、抗红白血病药物
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262864A (en) 1968-03-29 1972-02-09 Glaxo Lab Ltd Diazacarbazoles
PL175347B1 (pl) 1992-04-03 1998-12-31 Upjohn Co Trójpierścieniowe heterocykliczne aminy aktywne farmaceutycznie
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
HUP9900330A3 (en) 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
WO1998042708A2 (en) 1997-01-08 1998-10-01 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
ATE315390T1 (de) 1998-11-17 2006-02-15 Smithkline Beecham Corp Zyklische polyamine zur behandlung der thrombozytopenie
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
EP1175421A1 (en) 1999-04-30 2002-01-30 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
EP1189609A4 (en) 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
WO2001017349A1 (en) 1999-09-10 2001-03-15 Smithkline Beckman Corporation Thrombopoietin mimetics
EP1223944B1 (en) 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietin mimetics
WO2001034585A1 (en) 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
JP2003515560A (ja) 1999-12-06 2003-05-07 スミスクライン・ビーチャム・コーポレイション トロンボポイエチン模倣物
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7241783B2 (en) 2000-12-19 2007-07-10 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2002309703A1 (en) * 2001-05-09 2002-11-18 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1581527A4 (en) 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
CA2565581C (en) 2003-05-02 2014-07-08 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
ES2344007T3 (es) * 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
MX2007013624A (es) * 2005-04-28 2008-02-12 Supergen Inc Inhibidores de proteina cinasa.
PL1910338T3 (pl) 2005-07-14 2011-02-28 Irm Llc Związki heterotetracykliczne jako mimetyki TPO
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
WO2007022269A2 (en) 2005-08-15 2007-02-22 Irm Llc Compounds and compositions as tpo mimetics
EP2044956A4 (en) 2006-06-14 2010-08-11 Chugai Pharmaceutical Co Ltd PROMOTER OF THE PROLIFERATION OF HEMATOPOIETIC STEM CELLS
JP2008050355A (ja) 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP2155862A2 (en) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
WO2009004329A1 (en) 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
JP2010193879A (ja) 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
WO2011056739A1 (en) * 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
EP2686320B1 (en) 2011-03-15 2016-05-18 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
CA2862140C (en) 2012-01-27 2020-04-21 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Also Published As

Publication number Publication date
SMT201900360T1 (it) 2019-07-11
JP6250556B2 (ja) 2017-12-20
CN104144931B (zh) 2018-04-10
EP2807165A4 (en) 2015-08-26
EP2807165B1 (en) 2019-05-15
BR112014018524A2 (pt) 2021-06-08
AU2013212457B2 (en) 2017-02-16
EP2807165A1 (en) 2014-12-03
US20160222017A1 (en) 2016-08-04
PL2807165T3 (pl) 2019-09-30
LT2807165T (lt) 2019-07-25
HUE044070T2 (hu) 2019-09-30
JP2015504902A (ja) 2015-02-16
HUE044070T4 (hu) 2019-12-30
PT2807165T (pt) 2019-07-12
ES2733946T3 (es) 2019-12-03
RS59002B1 (sr) 2019-08-30
BR112014018524A8 (pt) 2017-07-11
CY1121799T1 (el) 2020-07-31
IL233587A0 (en) 2014-08-31
HK1203945A1 (en) 2015-11-06
US20170334904A1 (en) 2017-11-23
US20150011543A1 (en) 2015-01-08
KR20140121454A (ko) 2014-10-15
KR102098122B1 (ko) 2020-04-07
WO2013110198A1 (en) 2013-08-01
AU2013212457A1 (en) 2014-09-18
SG11201404241SA (en) 2014-08-28
SI2807165T1 (sl) 2019-08-30
CA2862140C (en) 2020-04-21
CN104144931A (zh) 2014-11-12
BR112014018524B1 (pt) 2023-03-28
US9409906B2 (en) 2016-08-09
US10336747B2 (en) 2019-07-02
HRP20191189T1 (hr) 2019-10-04
IL233587B (en) 2019-11-28
CA2862140A1 (en) 2013-08-01
DK2807165T3 (da) 2019-07-15
NZ627188A (en) 2015-12-24

Similar Documents

Publication Publication Date Title
TR201909582T4 (tr) Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi.
CA2946446C (en) Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
AU2018253115B2 (en) Aryl hydrocarbon receptor antagonists and uses thereof
AU2023241382A1 (en) Compounds and use thereof in the expansion of stem cells and/or progenitor cells
HK1203945B (en) Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells